ArticleLangenbeck's archives of surgery2025
Transanal endoscopic microsurgery in the treatment of rectal neuroendocrine tumors: a retrospective 10-year single-center experience.
Article in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rectal neuroendocrine tumors: Update.World journal of gastrointestinal oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTransanal endoscopic surgery is a recommended full-thickness resection technique for the treatment of rectal neuroendocrine tumors. We aimed to compare the efficacy, safety and follow-up of patients with rectal neuroendocrine tumors treated with transanal endoscopic microsurgery in the primary setting and as salvage therapy after non-radical endoscopic polypectomy.
methodsA retrospective analysis of a 10-year database of patients treated with transanal endoscopic microsurgery was performed. The procedure-related measures, including duration of the procedure, adverse events, and patient-related measures, including age, gender, tumor size, grading, and length of follow-up, were obtained. We compared the primary TEM group with the salvage group.
resultsIn total, 30 patients with rectal neuroendocrine tumors were included in the study; 13 of them received primary treatment and 17 salvage therapy of the scar. Patients receiving primary treatment were significantly older (60.5 vs. 51.7 years). There were no significant differences in patient gender, tumor size and grading, length of follow-up, hospital stay or procedure time. The R0 resection rate was 92.3% in the primary treatment group. Adverse events were mild or managed with endoscopic treatment. Follow-up was slightly but not significantly longer in the primary treatment group and showed no recurrences in both groups of patients.
conclusionsTransanal endoscopic microsurgery is safe and effective for both primary and salvage treatment of rectal neuroendocrine tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.